Abstract
Background: Statins are a well-established class of drugs in both preventing coronary events and treating cardiovascular atherosclerotic disease, however their use in heart failure is still in debate.
Objectives: To establish whether statins' pleiotropic actions in endothelium, inflammation, remodeling of the heart and anti-arrhythmic potential may be in favorable of heart failure patients.
Methods: We proceed to literature search of English bibliography under the terms heart failure, statins, 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Results: Various experimental and clinical trials on the use of statins in the different subtypes of heart failure according to the ejection fraction of the left ventricle have been conducted to conclude whether statins should be part of their patients' treatment. The evidence shows that the subgroup of patients with ischemic heart disease and those with preserved ejection fraction seems to have better results from the use of statins although randomized control trial in the total heart failure population did not show any benefit in mortality.
Conclusion: Statins may be beneficial to left ventricle systolic and diastolic performance of heart failure patients however their result in mortality cannot be established based on current evidence.
Keywords: Statins, heart failure, left ventricle ejection fraction, left ventricle remodeling, dyslipidemia, pleiotropic effects.
Current Pharmaceutical Design
Title:Statins and Left Ventricular Function
Volume: 23 Issue: 46
Author(s): Agamemnon Bakakos, Evangelos Oikonomou*, Georgia Vogiatzi, Gerasimos Siasos, Sotiris Tsalamandris, Alexios Antonopoulos, Costas Mourouzis, Petros Fountoulakis, Manolis Vavuranakis and Dimitris Tousoulis
Affiliation:
- 1st Department of Cardiology, ‘Hippokration' Hospital, University of Athens Medical School, Athens,Greece
Keywords: Statins, heart failure, left ventricle ejection fraction, left ventricle remodeling, dyslipidemia, pleiotropic effects.
Abstract: Background: Statins are a well-established class of drugs in both preventing coronary events and treating cardiovascular atherosclerotic disease, however their use in heart failure is still in debate.
Objectives: To establish whether statins' pleiotropic actions in endothelium, inflammation, remodeling of the heart and anti-arrhythmic potential may be in favorable of heart failure patients.
Methods: We proceed to literature search of English bibliography under the terms heart failure, statins, 3- hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Results: Various experimental and clinical trials on the use of statins in the different subtypes of heart failure according to the ejection fraction of the left ventricle have been conducted to conclude whether statins should be part of their patients' treatment. The evidence shows that the subgroup of patients with ischemic heart disease and those with preserved ejection fraction seems to have better results from the use of statins although randomized control trial in the total heart failure population did not show any benefit in mortality.
Conclusion: Statins may be beneficial to left ventricle systolic and diastolic performance of heart failure patients however their result in mortality cannot be established based on current evidence.
Export Options
About this article
Cite this article as:
Bakakos Agamemnon, Oikonomou Evangelos*, Vogiatzi Georgia, Siasos Gerasimos , Tsalamandris Sotiris, Antonopoulos Alexios , Mourouzis Costas, Fountoulakis Petros , Vavuranakis Manolis and Tousoulis Dimitris , Statins and Left Ventricular Function, Current Pharmaceutical Design 2017; 23 (46) . https://dx.doi.org/10.2174/1381612823666170926125754
DOI https://dx.doi.org/10.2174/1381612823666170926125754 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Antiplatelet Therapies: Aspirin at the Heart of New Directions
Cardiovascular & Hematological Disorders-Drug Targets Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Adjuvant Therapies of COVID-19 - A Literature Review
Coronaviruses Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood Serum Atherogenicity and Coronary Artery Calcification
Current Pharmaceutical Design Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Novelty in Treatment of Pulmonary Fibrosis: Pulmonary Hypertension Drugs and Others
Cardiovascular & Hematological Agents in Medicinal Chemistry In the Search of the Vulnerable Plaque: Current Diagnostic Techniques and Future Directions
Vascular Disease Prevention (Discontinued) Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Obesity and Herbal Drug Research: Exploring the Safer Alternative and Lead Molecule
Current Traditional Medicine Safety of Therapeutics Used in Management of Patent Ductus Arteriosus in Preterm Infants
Current Drug Safety Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics